|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02427 GUANZE MEDICAL
Nominal 
0.465 0.000 (0.000%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 155,740 | -0.213% | 156,072 | 177,112 | 211,076 | 184,435 |
| Cost of Sales | (92,954) | 31.538% | (70,667) | (96,136) | (135,377) | (122,860) |
| Gross Profit | 62,786 | -26.484% | 85,405 | 80,976 | 75,699 | 61,575 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 26,309 | -31.930% | 38,650 | 29,962 | 33,057 | 39,003 | |
| Taxation | (8,859) | -17.422% | (10,728) | (11,676) | (9,989) | (9,960) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (246) | -30.704% | (355) | (342) | (133) | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 17,204 | -37.592% | 27,567 | 17,944 | 22,935 | 29,043 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (6) | -- | 18 | 999 | 556 | 761 |
| Depreciation & Amortisation | 7,274 | 21.092% | 6,007 | 5,290 | 4,418 | 3,287 |
| Directors' Emoluments | 2,588 | 24.423% | 2,080 | 313 | 234 | 198 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 2.000 | -33.333% | 3.000 | 2.000 | 3.000 | -- |
| DPS (cts) | 0.000 | -- | 1.903 | 1.840 | -- | -- |
| Dividend Payout Ratio (%) | -- | -- | 63.440% | 91.992% | -- | -- |
| Cash flow per share ($) | 0.023 | -- | 0.009 | 0.012 | 0.004 | -- |
| NBV per share ($) | 0.273 | -- | 0.284 | 0.274 | -- | -- |
| Remarks: | Real time quote last updated: 28/10/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,368 |
| %Change | -- |
| EPS / (LPS) | RMB 0.003 |
| NBV Per Share (¥) | RMB 0.277 |